Grifols SA
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Large accelerated filer
Business Address
1585 BROADWAY, NEW YORK, NY, 10036
Mailing Address
1585 BROADWAY, NEW YORK, NY, 10036
Phone
212-969-3335
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | April 17, 2026 | View on SEC |
| 6-K Foreign company current report | April 14, 2026 | View on SEC |
| 6-K Foreign company current report | March 24, 2026 | View on SEC |
| 6-K Foreign company current report | February 26, 2026 | View on SEC |
| 6-K Foreign company current report | February 26, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 6-K Foreign company current report | January 8, 2026 | View on SEC |
| 6-K Foreign company current report | December 16, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
Annual Reports
20-F
April 17, 2026
- Divested 20% stake in Shanghai RAAS for €1.6 billion to accelerate debt reduction.
- Achieved 7% constant currency revenue growth driven by strong demand for Immunoglobulin and Albumin.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.